SureTrader Stock Hero Advertisement SureTrader SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator mick, Foxwoods Man, drkazmd65, maverick1856
Search This Board:
Last Post: 5/24/2015 12:48:50 AM - Followers: 162 - Board type: Free - Posts Today: 1

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/



Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
  2. The scientific, clinical, and commercial development of the medicine and
  3. CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  
  2. Teva Pharmaceuticals Industries Ltd.
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  
  3.  
  4. Orient Europharma Co. Ltd.
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  
  5.  
  6. IDC-GP Pharm LLC 
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  
  7.  

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
Wiki
CVM News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 05/22/2015 04:34:33 PM
CVM News: CEL-SCI Prices up to $16 Million Public Offering of Common Stock and Warrants 05/22/2015 09:03:00 AM
CVM News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 05/21/2015 04:47:05 PM
CVM News: CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants 05/21/2015 04:32:00 PM
CVM News: Current Report Filing (8-k) 05/13/2015 09:01:49 AM
PostSubject
#6818  Sticky Note CEL-SCI (NYSE: CVM) is the most undervalued Phase maverick1856 02/27/15 01:26:17 PM
#6737  Sticky Note And then there were 20,.... drkazmd65 02/19/15 11:36:47 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#7108   Cel-Sci Corp. Common (CVM) mick 05/24/15 12:48:50 AM
#7107   Geert will get his million $ back with Foxwoods Man 05/23/15 01:46:58 PM
#7106   The warrants do NOT have a market, but sab63090 05/23/15 11:49:30 AM
#7105   Ok...I'm kinda confused with this offering. Why would Foxwoods Man 05/23/15 08:01:33 AM
#7104   I see, I guess, in the offer that Turney 05/23/15 01:06:43 AM
#7103   Actually,... I think you have more than just drkazmd65 05/22/15 01:05:17 PM
#7102   Oops...I just saw the opening price and volume..guess Foxwoods Man 05/22/15 09:40:55 AM
#7101   So someone PLEASE tell me I have this Foxwoods Man 05/22/15 09:35:22 AM
#7100   Thanks for the insight.... Foxwoods Man 05/20/15 05:10:52 PM
#7099   stockcharts.com/c-sc/sc?chart=CVM,uu[900,a]decly[dk][pb200!b300!b400!b500 mick 05/20/15 01:56:44 PM
#7098   FALLING FALLING FALLING CVM mick 05/20/15 01:56:21 PM
#7097   Yup..I posted that I thought the dilution would Foxwoods Man 05/19/15 02:39:56 PM
#7096   Well - there was some time-lag,.... but this drkazmd65 05/19/15 12:08:04 PM
#7095   You are not taking in to consideration the Turney 05/14/15 06:40:22 AM
#7094   The Global study approach was designed by Cel-Sci, mikedel 05/13/15 01:42:18 PM
#7093   Mike - this is a global phase 3 maverick1856 05/13/15 10:43:22 AM
#7092   Why so many Centers? mikedel 05/13/15 09:39:52 AM
#7091   This news leads me to believe CVM will Turney 05/12/15 01:27:58 PM
#7090   here are some interesting excerpts from the Annual Report: maverick1856 05/09/15 01:58:16 PM
#7089   Thanks for the information maverick - especially the drkazmd65 05/09/15 11:11:20 AM
#7088   Yes - scroll down and open the pdf maverick1856 05/09/15 10:00:48 AM
#7087   There is only 1 thing worth taking special sab63090 05/08/15 04:19:49 PM
#7086   stockcharts.com/c-sc/sc?r=73376&chart=cvm,uu[305,a]dacayaci[pb20!b50][dg] mick 05/08/15 02:57:04 PM
#7085   Can anybody out there read the ARS document(s) drkazmd65 05/08/15 12:32:42 PM
#7084   This should be the last of the funding ed2000 05/08/15 10:56:38 AM
#7083   So? 150m x 10= 1500m == meaning a Turney 05/08/15 08:13:53 AM
#7082   Totally agree with you on Geert's reputation. ducruacuteo11 05/07/15 05:48:28 PM
#7081   150M shares outstanding after offering. Yikes! ducruacuteo11 05/07/15 05:46:10 PM
#7080   I pretty much agree with you that we sab63090 05/07/15 08:11:53 AM
#7079   Big drop will happen when financing deal is mikedel 05/07/15 07:43:57 AM
#7078   The price drop yesterday wasn't as bad as Foxwoods Man 05/07/15 07:11:58 AM
#7077   Yeah, I agree. As I stated earlier, sab63090 05/06/15 01:45:36 PM
#7076   Ok...I'm kinda confused with this offering. Why would Foxwoods Man 05/06/15 12:54:30 PM
#7075   Whatever it is, in three years, we will ducruacuteo11 05/06/15 12:37:35 PM
#7074   IF FBR takes the green shoe (add'l shares, sab63090 05/06/15 12:01:29 PM
#7073   The offer price is $1.03 (price as of ducruacuteo11 05/06/15 10:46:15 AM
#7072   No Offering Price. mikedel 05/06/15 08:36:23 AM
#7071   Oops...0.85 in early pre-market Foxwoods Man 05/06/15 08:06:52 AM
#7070   So since there are around 91 million common Foxwoods Man 05/06/15 07:37:49 AM
#7069   Thanks for that info. Enrollment now extends to sab63090 05/06/15 07:37:26 AM
#7068   Just bubbling with good news today: Foxwoods Man 05/06/15 07:22:31 AM
#7067   I agree and price discovery at this point sab63090 05/06/15 07:13:43 AM
#7066   Well - we all figured something like this drkazmd65 05/06/15 06:55:34 AM
#7065   The size is probably testament to the investor maverick1856 05/06/15 06:52:12 AM
#7064   $35 million offering...that's a big gulp!... Foxwoods Man 05/06/15 06:21:04 AM
#7063   Cel-Sci Corp. Common (CVM) mick 05/04/15 02:15:07 PM
#7062   Agreed,.... it's not 'bad' news,.... but it is drkazmd65 05/01/15 10:23:11 AM
#7061   Well....good news, mediocre news... Foxwoods Man 05/01/15 08:17:11 AM
#7060   If it is all bull, then you got ducruacuteo11 04/27/15 05:42:51 PM
#7059   I don't think there has been a stock Turney 04/26/15 09:12:41 PM
PostSubject